Is Myoclonus a Positive Finding on an AIMS Exam?
No, myoclonus is not what the AIMS exam is designed to detect—the AIMS (Abnormal Involuntary Movement Scale) specifically assesses tardive dyskinesia from antipsychotic medications, not myoclonus. These are fundamentally different movement disorders with distinct etiologies, characteristics, and clinical contexts.
Understanding the Distinction
What AIMS Actually Measures
The AIMS examination is a standardized tool developed to screen for and quantify tardive dyskinesia—a medication-induced movement disorder characterized by repetitive, involuntary movements typically affecting the face, mouth, tongue, and extremities 1, 2. The scale evaluates choreiform movements, athetoid movements, and other dyskinetic patterns that emerge as a side effect of chronic dopamine receptor blockade from antipsychotic medications 3.
What Myoclonus Actually Is
Myoclonus consists of sudden, brief (10-50 milliseconds), shock-like involuntary muscle jerks caused by muscular contractions or inhibitions 4, 5. This is a completely different movement phenomenology from tardive dyskinesia. Myoclonus can be:
- Focal, multifocal, or generalized in distribution
- Cortical or subcortical in origin
- Associated with epilepsy, post-hypoxic brain injury, metabolic disorders, or neurodegenerative conditions 6, 7
Key Clinical Differences
Movement characteristics:
- Tardive dyskinesia (AIMS target): Repetitive, stereotyped, flowing movements; often choreiform or athetoid; predominantly orofacial
- Myoclonus: Brief, shock-like jerks; non-rhythmic; can affect any body region 5
Etiology:
- Tardive dyskinesia: Chronic antipsychotic medication exposure
- Myoclonus: Diverse causes including epilepsy, hypoxic-ischemic injury, metabolic derangements, neurodegenerative diseases 8, 5
Duration of movements:
- Tardive dyskinesia: Sustained, continuous movements
- Myoclonus: Extremely brief (milliseconds), jerking movements 5
Important Clinical Context
The confusion may arise because the term "myoclonus" appears in syncope guidelines 9 where it describes brief jerking movements that can occur during loss of consciousness. However, this usage refers to the descriptive term for the movement pattern, not a formal diagnosis that would be captured on an AIMS examination.
If you observe myoclonic movements during a medication evaluation, this warrants:
- Neurological consultation rather than simply documenting on AIMS
- EEG evaluation to assess for epileptiform activity 6
- Investigation for underlying neurological conditions
- Consideration of whether the movements are actually myoclonus versus a different movement disorder
Practical Guidance
When performing movement disorder assessments:
- Use AIMS specifically for tardive dyskinesia screening in patients on chronic antipsychotics 1, 2
- Document myoclonus separately with detailed description of timing, distribution, triggers, and associated symptoms
- Do not conflate these distinct movement disorders as they require entirely different diagnostic and therapeutic approaches 3
- Obtain neurophysiological studies (EEG, EMG) if true myoclonus is suspected to determine cortical versus subcortical origin 7, 5
The AIMS is a specialized tool for one specific drug-induced movement disorder and should not be used as a general movement disorder assessment instrument.